Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...

Cheese is one of the few foods that can start a family argument without anyone leaving the kitchen and lately, it has managed ...

Pfizer is penning a cancer discovery pact with Cartography Biosciences that could max out at $865 million biobucks. | Pfizer ...

Let’s dive into details regarding each of the evaluated factors, but first, for quick context: With $143 Bil in market capitalization, Pfizer offers biopharmaceutical products which include ...

Pfizer recently announced its guidance for 2026. One thing seems clear: Its financial results won't get much stronger. It ...

The partnership brings together Pfizer’s scientific data and therapeutic expertise with Boltz’s open-source AI foundation ...

Investing $12,000 in the stock today would allow you to collect approximately $600 in dividends per year. Combined with the ...

Pfizer Inc. and Boltz, PBC, an applied AI research lab, today announced a strategic collaboration to empower scientists ...

Pfizer's 2026 revenue midpoint of $61B and EPS midpoint of $2.90 decline YoY, reflecting persisting headwinds. Read more on ...

A patient died after receiving Pfizer Inc.’s drug for hemophilia, marking another setback for the company in the treatment of blood disorders.

A patient who was being treated with Pfizer's hemophilia drug, Hympavzi, as part of a long-term study died after experiencing serious side effects, the company said.

Pfizer Inc. is cutting hundreds of jobs in Switzerland as part of a multi-year program to reduce costs, according to people familiar with the matter.